首页 | 本学科首页   官方微博 | 高级检索  
   检索      

纯化自体外周血CD34^+细胞移植治疗肢体重度缺血的中期疗效
引用本文:董智慧,;魏征,;符伟国,;廉维帅,;陈斌,;郭大乔,;张祥满,;王志梅,;邹善华,;徐欣,;蒋俊豪,;杨珏,;史振宇,;竺挺,;王玉琦.纯化自体外周血CD34^+细胞移植治疗肢体重度缺血的中期疗效[J].中华细胞与干细胞杂志(电子版),2014(3):36-40.
作者姓名:董智慧  ;魏征  ;符伟国  ;廉维帅  ;陈斌  ;郭大乔  ;张祥满  ;王志梅  ;邹善华  ;徐欣  ;蒋俊豪  ;杨珏  ;史振宇  ;竺挺  ;王玉琦
作者单位:[1]复旦大学附属中山医院血管外科,上海200032; [2]复旦大学附属中山医院血液科,上海200032
基金项目:上海市人才发展资金(2010017)
摘    要:目的探讨纯化CD34^+细胞移植治疗肢体重度缺血的中期疗效。方法自2009年5月至2011年12月录入30例肢体重度缺血患者,男性29例,女性1例,平均年龄43 ± 12岁(23 - 75岁),均不具备外科血管重建条件,共治疗31条下肢和4条上肢。G-CSF(5-10μg/kg)动员,第5天采集外周血单个核细胞,分选获得纯化CD34^+细胞,肢体肌肉局部注射。根据移植细胞数分为3组:低剂量组(105/kg)、中剂量组(5 × 105/kg)和高剂量组(106/kg)。结果随访16 - 48个月,1个月和2个月时Wong-Baker FACES疼痛评分由术前7 ± 2降到3 ± 3(P〈 0.001)和1 ± 2(P〈 0.001)。术后3个月和6个月:最长无痛步行时间由术前的(5 ± 3)min分别延长至(12 ± 6)min(P〈 0.001)和(19 ± 5)min(P〈 0.001);踝肱指数由术前的0.44 ± 0.20提高至0.62 ± 0.18(P= 0.04)和0.66 ± 0.14(P〈 0.001);经皮氧分压由术前(26 ± 11)mmHg分别上升至(42 ± 11)mmHg(P 〈 0.001)和(56 ± 12)mmHg(P〈 0.001)。16例溃疡患者愈合11例。Kaplan Meier生存分析法计算16个月保肢率为84﹪(95﹪可信区间为0.63 - 0.94)。3个不同剂量组之间的比较,治疗效果差异无统计学意义,除了1个月时WFPRSC检测结果显示:高剂量组明显优于低、中剂量组。结论纯化自体外周血CD34^+细胞移植治疗肢体重度缺血性疾病安全、可行,能够较为持久地缓解缺血,挽救肢体,改善患者生活质量。

关 键 词:细胞移植  CD34  四肢  缺血

Mid-term outcomes of transplantation of purified CD34^+ cells from peripheral blood in treatment of critical limb ischemia
Institution:Dong Zhihui, Wei Zheng, Fu Weiguo, Lian Weishuai, Chen Bin, Guo Daqiao, Zhang Xiangman, Wang Zhimei, Zou Shanhua, Xu Xin, Jiang Junhao, Yang Jue, Shi Zhenyu, Zhu Ting, Wang Yuqi.( Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China)
Abstract:Objective To evaluate the mid-term outcomes of transplantation of purified peripheral blood CD34^+ cells in treatment of critical limb ischemia. Methods From May 2009 to November 2011, 30 patients with critical limb ischemia underwent transplantation of purified peripheral blood CD34^+ cells. Mean age was 43 ±12 years (23-75), and all patients were not suitable for surgical or endovascular revascularization. G-CSF was subcutaneously injected for 5 days before apheresis for peripheral blood mononuclear cells. Then CliniMACS system was used to isolate CD34^+ cells. The patients were divided into 3 groups: low-dose (105/kg); medium-dose (5×10^5)/kg; and high-dose (106/kg). The outcomes were compared among 3 groups. Results The follow-up was accomplished in 27 cases, ranging from 16 - 48 months ( 30 ± 8 ). One month after transplantation, the rest pain was obviously relieved in all cases, and the Wong-Baker FACES pain rating score significantly decreased from 7 ± 2 to 3 ± 3 (0-2), P 〈 0.001. The peak pain-flee walking time was significantly improved from (5 ^+ 3) min to ( 12 ± 6) min at 3 month and ( 19 ± 5) min at 6 month respectively. The ankle- brachial index increased from 0.44 ^+ 0.20 to 0.62 ± 0.18 at 3 month and 0.66 ^+ 0.14 at 6 month, respectively. Of 14 cases with ulcer, 11 healed. Transcutaneous partial oxygen pressure rose from (26 ± 11 ) mmHg to (42 ± 11 ) mmHg at 3 month and (56 ± 12) mmHg at 6 month, respectively. No serious complications were observed either per^+operatively or postoperatively. Conclusions Transplantation of purified peripheral blood CD34^+ cells appeared to be effective and safe for critical limb ischemia.
Keywords:Cell therapy  CD34^+  Extremities  Ischemia
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号